ZihaiLiMDPhD

Oncology • Columbus, OH

Founding Director, Pelotonia Institute for Immuno-Oncology

Join to view full profile

Dr. Li is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Li's full profile

Already have an account?

Office
460 W 12th Ave
Columbus, OH 43210
Phone+1 614-366-0172

Summary

I am a cancer immunologist and medical oncologist with passion in discovering and translating knowledge to improve care of patients with cancer.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1997 - 1999
Montefiore Medical CenterResidency, 1994 - 1997
Henan Medicine UniversityClass of 1984

Certifications & Licensure

OH State Medical License 2019 - 2026
SC State Medical License 2010 - 2019
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Elected member of ASCI, AAP and AAAS

Publications & Presentations

PubMed

A novel TLR4 accessory molecule drives hepatic oncogenesis through tumor-associated macrophages.
Doyeon Kim, Carter A Allen, Dongjun Chung, Lingbin Meng, Xiaoli Zhang
Cancer Letters. 2025-04-01
HuR inhibition reduces post-ischemic cardiac remodeling by dampening myocyte-dependent inflammatory gene expression and the innate immune response.
Samuel Slone, Sarah R Anthony, Lisa C Green, Sharon Parkins, Pooja Acharya
FASEB Journal. 2025-03-31
Recent advances in therapeutic strategies for non-small cell lung cancer.
Po-Lan Su, Naoki Furuya, Alahmadi Asrar, Christian Rolfo, Zihai Li
Journal of Hematology & Oncology. 2025-03-27

Press Mentions

Research Area of Concentration: Dr. Peter Mohler Shares UpdateAugust 10th, 2023

Grant Support

Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung CancerOHIO STATE UNIVERSITY2024–2029
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial MetabolismOHIO STATE UNIVERSITY2021–2026
Targeting GRP94-TGF-beta Pathway for Cancer ImmunotherapyOHIO STATE UNIVERSITY2021–2026
Targeting GRP94-TGF-beta Pathway for Cancer ImmunotherapyOHIO STATE UNIVERSITY2021–2026
Overcoming hypoxic resistance to anti-cancer therapyOHIO STATE UNIVERSITY2020–2025